Mark Hahn - Aug 1, 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Aug 1, 2022
Transactions value $
-$315,106
Form type
4
Date filed
8/3/2022, 04:10 PM
Previous filing
May 5, 2022
Next filing
Aug 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Tax liability -$306K -455K -2.96% $0.67* 14.9M Aug 1, 2022 Direct F1, F2, F3
transaction VRNA Ordinary Shares Sale -$9.21K -13.2K -0.09% $0.70* 14.9M Aug 1, 2022 Direct F1, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
F3 The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 29, 2022 divided by eight (8).
F4 The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.
F5 The price reported represents the sale price of the ADSs divided by eight (8).
F6 Consists of (i) 7,002,376 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 875,297 ADSs); and (ii) 7,911,120 Ordinary Shares underlying 988,890 ADSs.